
Benitec Biopharma Inc.: updates and filings
Price
$7.92
November 20, 2026Market cap $392M
What Ploutos Investor adds for Benitec Biopharma
Part of Ploutos Investor, €9.99 a month
- The full history: 8 fiscal years, from FY2019
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Nov 13, 2026next Feb 12, 2027
A rough estimate from when it has reported before, which has varied. The company announces the date itself.
November 2026
September 2026
May 2026
February 2026
December 2025
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 13, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Nov 13, 2026Results of operations, amended articles or bylawsForm8-K
- Oct 28, 2026Regulation FD disclosureForm8-K
- Oct 20, 2026Additional annual meeting materialFormDEFA14A
- Oct 20, 2026Annual meeting proxy statementFormDEF 14A
- Oct 5, 2026Regulation FD disclosureForm8-K
- Sep 30, 2026Change of auditorForm8-K
- Sep 24, 2026Change of auditorForm8-K
- Sep 21, 2026FilingFormEFFECT
- Sep 14, 2026Shelf registration for future offeringsFormS-3
- Sep 14, 2026Annual reportfor the period to Jun 30, 2026Form10-K
- Sep 14, 2026Results of operationsForm8-K
- May 29, 2026Officer or director changeForm8-K
- May 14, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- May 14, 2026Results of operationsForm8-K
- Apr 3, 2026Letter from the SECFormUPLOAD
- Mar 20, 2026Correspondence with the SECFormCORRESP
- Mar 20, 2026Annual report (amendment)for the period to Jun 30, 2025Form10-K/A
- Feb 24, 2026Letter from the SECFormUPLOAD
- Feb 12, 2026Results of operationsForm8-K
- Feb 12, 2026Quarterly reportfor the period to Dec 31, 2025Form10-Q
- Feb 10, 2026FilingFormEFFECT
- Feb 6, 2026Correspondence with the SECFormCORRESP
- Feb 6, 2026Letter from the SECFormUPLOAD
- Jan 30, 2026Shelf registration for future offeringsFormS-3
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 13, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Nov 13, 2026 | 8-K | Results of operations, amended articles or bylaws | Document |
| Oct 28, 2026 | 8-K | Regulation FD disclosure | Document |
| Oct 20, 2026 | DEFA14A | Additional annual meeting material | Document |
| Oct 20, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Oct 5, 2026 | 8-K | Regulation FD disclosure | Document |
| Sep 30, 2026 | 8-K | Change of auditor | Document |
| Sep 24, 2026 | 8-K | Change of auditor | Document |
| Sep 21, 2026 | EFFECT | Filing | Document |
| Sep 14, 2026 | S-3 | Shelf registration for future offerings | Document |
| Sep 14, 2026 | 10-K | Annual reportfor the period to Jun 30, 2026 | Document |
| Sep 14, 2026 | 8-K | Results of operations | Document |
| May 29, 2026 | 8-K | Officer or director change | Document |
| May 14, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| May 14, 2026 | 8-K | Results of operations | Document |
| Apr 3, 2026 | UPLOAD | Letter from the SEC | Document |
| Mar 20, 2026 | CORRESP | Correspondence with the SEC | Document |
| Mar 20, 2026 | 10-K/A | Annual report (amendment)for the period to Jun 30, 2025 | Document |
| Feb 24, 2026 | UPLOAD | Letter from the SEC | Document |
| Feb 12, 2026 | 8-K | Results of operations | Document |
| Feb 12, 2026 | 10-Q | Quarterly reportfor the period to Dec 31, 2025 | Document |
| Feb 10, 2026 | EFFECT | Filing | Document |
| Feb 6, 2026 | CORRESP | Correspondence with the SEC | Document |
| Feb 6, 2026 | UPLOAD | Letter from the SEC | Document |
| Jan 30, 2026 | S-3 | Shelf registration for future offerings | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Apr 15, 2020.
The full analysis
What do Benitec Biopharma's filings show?
The filings are where every one of Benitec Biopharma's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.